Cutaneous drug reactions in childhood

Abstract

Cutaneous Drug reactions (CDR) are adverse admissions or harmful effects of drugs according to the definition by the World Health Organization. One of the early lessons learned in dermatology training is “any drug, any rash.” Drug-related cutaneous reactions can be daunting, even for the experienced dermatologist and pediatrics. There have been more than 25 different patterns described in the literature. The most commonly affected organs are the skin in drug reactions and dermatological examination is very important in the diagnosis for drug reactions. Cutaneous drug reactions should be distinguished from viral exanthema which is the most commonly seen in children, and it often is not easily. In treatment of cutaneous drug reactions, the first step is to immediately discontinue the susceptible drug. In this article, the approach to cutaneous drug reactions in children will be evaluated in accordance with current literature. J Clin Exp Invest 2014; 5 (4): 632-638

Keywords

• Cutaneous, drug, reaction, child

Polikistik over sendromunda ovulasyon indüksiyonu

Öz

Kutanöz İlaç Reaksiyonları (KİR) Dünya sağlık örgütü tanımlamasına göre ilaçların deride oluşturduğu istenmeyen ya da zararlı olabilen etkileridir. Dermatoloji eğitiminde ilk derslerden biri ''herhangi bir ilaç herhangi bir döküntüye yol açabilir'' dir. İlaca bağlı gelişen kutanöz reaksiyonlar bazen deneyimli dermatolog ve pediatristleri dahi zor durumda bırakabilecek nitelikte olabilirler. Literatürde şimdiye kadar 25\'ten fazla farklı klinik şekilde ilaca bağlı kutanöz reaksiyon tanımlanmıştır. İlaç reaksiyonlarında en sık etkilenen organ deridir ve ilaç reaksiyonu tanısını koymada dermatolojik muayene çok önemlidir. Çocuklarda KİR bu yaş grubunda çok sık görülen viral ekzantemlerden ayırt edilmelidir ve bu çoğu zaman kolay olmamaktadır. İlaç reaksiyonların tedavisinde ilk yapılması gereken şüphelenilen ilacın kesilmesidir. Bu makalede pediatrik kutanöz ilaç reaksiyonlarına yaklaşım güncel literatür eşliğinde sunulmuştur.

Anahtar Kelimeler

• Kutanöz, ilaç, reaksiyon, çocuk

Kaynakça

1. Boyvat A. İlaç erupsiyonlarında patogenez ve klinik özellikler. Türkiye Klinikleri J Dermatol 2008;1:47-57.
2. Mirakian R, Ewan PW, Durham SR, et al. BSACI guide- lines for the management of drug allergy. Clin Exp Al- lergy 2009;39:43-61.
3. Erkek E: Kutanoz İlac Reaksiyonları. In: Tuzun Y, Gurer MA, Serdaroğlu S, Oğuz O, Aksungur VL (editorler). Dermatoloji. 3. Baskı, İstanbul: Nobel Tıp Kitabevleri, 2008:269-316.
4. Martin T, Hui L: Severe cutaneous adverse drug re- actions: a review on epidemiology, etiology, clini- cal manifestation and pathogenesis. Chin Med J 2008;121:756-761.
5. Schnyder B. Approach to the patient with drug allergy. Immunol Allergy Clin North Am 2009;29:405-418.
6. Edwards IR, Aronson JK. Adverse drug reactions: de- finitions, classification, diagnosis, management, sur- veillance. Lancet 2000;356:1255-1260.
7. Çelik G, Pichler WJ, Adkinson NF. Drug Allergy. In: Adkinson NF, Bochner BS, Busse WW, (eds). Allergy principles and practice. 7th ed. Philadelphia: Mosby- Elsevier Inc; 2009: 1205-1226.
8. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; Ameri- can College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010;105:259-273.

9. Solensky R, Mendelson LM. Drug Allergy. In: Leung DYM, Sampson HA, Geha R, (eds). Pediatric allergy: principles and practice. 2nd ed. Saunders: China; 2010:616-630.
10. Nayak S, Acharjya B. Adverse cutaneous drug reac- tion. Indian J Dermatol 2008;53:2-8.
11. DeShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA 1997;278:1895-906.
12. Noguera-Morel L, Hernández-Martín Á, Torrelo A. Cutaneous drug reactions in the pediatric population. Pediatr Clin North Am 2014;61:403-426.
13. Yazıcıoğlu M. Çocukluk çağında ilaç alerjilerine yakla- şım. Türk Ped Arş 2014; 49: 99-103.
14. Koren G. Protecting young children from life-threaten- ing drug toxicity. J Pediatr 2013;163:1249-1250.
15. Heelan K, Shear NH. Cutaneous drug reactions in children: an update. Paediatr Drugs 2013;15:493-503.
16. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy 2012;97:1-17.
17. Dinçer D. Dermatolojide İlaç Reaksiyonları. Turk J Dermatol 2013; 7: 179-184.
18. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients: A systematic review of the prospective and retrospective studies. Bandolier Extra 2002;35:1-16.
19. Star K, Noren GN, Nordin K, Edwards IR. Suspected adverse drug reactions reported for children world- wide: an exploratory study using VigiBase. Drug Saf 2011;34:415-428.
20. Menniti-Ippolito G, Raschetti R, Da Cas R, et al. Ac- tive monitoring of adverse drug reactions in children. Italian Paediatric Pharmacosurveillance Multicenter Group. Lancet 2000;355:1613-1614.
21. Rebelo Gomes E, Fonseca J, Araujo L, et al. Drug allergy claims in children: from self-reporting to con- firmed diagnosis. Clin Exp Allergy 2008;38:191-198.
22. Castro-Pastrana LI, Ghannadan R, Rieder MJ, et al. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacoge- nomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol 2011;18:e106-120.
23. Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice set- ting. Arch Dermatol 2000;136:849-854.
24. Roujeau JC, Stern RS. Severe adverse cutaneous re- actions to drugs. N Engl J Med 1994;331:1272-1285.
25. Huang HY, Luo XQ, Chan LS, et al: Cutaneous ad- verse drug reactions in a hospital-based Chinese pop- ulation. Clin Exp Dermatol 2011;36:135-141.
26. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39.
27. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001;137: 765-70.
28. Song JE, Sidbury R. An update on pediatric cu- taneous drug eruptions. Clin Dermatol. 2014 Jul- Aug;32:516-523.
29. Mortureux P, Leaute-Labreze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood: a prospective study. Arch Dermatol 1998;134:319-323.
30. Del Rosso JQ. Skin manifestations of drug reactions. Curr Allergy Asthma Rep 2002;2:282-287.
31. Bircher AJ. Uncomplicated drug-induced disseminat- ed exanthemas. Chem Immunol Allergy 2012;97:79- 97.
32. Segal AR, Doherty KM, Leggott J, et al. Cuta- neous reactions to drugs in children. Pediatrics 2007;120:e1082-1096.
33. Tolpinrud WL, Bunick CG, King BA. Serum sickness- like reaction: histopathology and case report. J Am Acad Dermatol 2011;65:e83-85.
34. Carroll MC, Yueng-Yue KA, Esterly NB, Drolet BA. Drug induced hypersensitivity syndrome in pediatric patients. Pediatrics 2001;108:485-492.
35. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reac- tion. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071-1080.
36. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens- Johnson syndrome, and erythema multi- forme. Arch Dermatol 1993;129:92-96.
37. Finkelstein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics 2011;128:723-728.
38. Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medi- cations as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009;123:e297-304.
39. Gue´gan S, Bastuji-Garin S, Poszepczynska-Guig- ne´ E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006;126:272-276.
40. Ozturk S, Ustun C, Pehlivan S, Ucak H. Acute Gener- alized Exanthematous Pustulosis Associated With Ti- gecycline. Ann Dermatol. Ann Dermatol 2014;26:246- 249.
41. Ersoy S, Paller AS, Mancini AJ. Acute generalized exanthematous pustulosis in children. Arch Dermatol 2004;140:1172-1173.
42. Öztürk S, Uçak H, Berçin S. Antiasitlerin nadir bir komplikasyonu: Siyah kıllı dil. Turkiye Klinikleri J Case Rep 2013;21:157-160.
43. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002;172:37-40.